163 related articles for article (PubMed ID: 38484730)
1. Analysis of treatment-related adverse events and wound complications of surgical resection after neoadjuvant chemoimmunotherapy for non-small cell lung cancer.
Li Y; Hu X; Zhang R; Wu N; Xia Q; Gu P
Int Wound J; 2024 Mar; 21(3):e14831. PubMed ID: 38484730
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer.
Liu W; Zhang T; Zhang Q; Li L; Xu C
BMC Pulm Med; 2022 Dec; 22(1):490. PubMed ID: 36582007
[TBL] [Abstract][Full Text] [Related]
3. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis.
Jiang J; Wang Y; Gao Y; Sugimura H; Minervini F; Uchino J; Halmos B; Yendamuri S; Velotta JB; Li M
Transl Lung Cancer Res; 2022 Feb; 11(2):277-294. PubMed ID: 35280319
[TBL] [Abstract][Full Text] [Related]
5. [Application of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC].
Wang H; Han Y
Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):822-832. PubMed ID: 38061884
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer.
Chen H; Yang W; Xue X; Li Y; Jin Z; Ji Z
Front Immunol; 2022; 13():986359. PubMed ID: 36059550
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of neoadjuvant immunotherapy protocols and cycles for non-small cell lung cancer: a systematic review and meta-analysis.
Wang H; Liang S; Yu Y; Han Y
Front Oncol; 2024; 14():1276549. PubMed ID: 38292925
[TBL] [Abstract][Full Text] [Related]
8. Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.
Hong T; Sun T; Zhang M; Liu X; Yuan Y; Dolo PR; Chen B; Zhang H
Thorac Cancer; 2021 Oct; 12(20):2796-2802. PubMed ID: 34463034
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and survival of neoadjuvant immunochemotherapy in operable non-small cell lung cancer: a systematic review and meta-analysis.
Zheng Y; Feng B; Chen J; You L
Front Immunol; 2023; 14():1273220. PubMed ID: 38106421
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis.
Sorin M; Prosty C; Ghaleb L; Nie K; Katergi K; Shahzad MH; Dubé LR; Atallah A; Swaby A; Dankner M; Crump T; Walsh LA; Fiset PO; Sepesi B; Forde PM; Cascone T; Provencio M; Spicer JD
JAMA Oncol; 2024 May; 10(5):621-633. PubMed ID: 38512301
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Neoadjuvant Chemoimmunotherapy in Resectable Esophageal Squamous Cell Carcinoma: A Meta-analysis.
Xu J; Yan C; Li Z; Cao Y; Duan H; Ke S
Ann Surg Oncol; 2023 Mar; 30(3):1597-1613. PubMed ID: 36380254
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial.
Zhu X; Sun L; Song N; He W; Xie B; Hu J; Zhang J; Yang J; Dai J; Bian D; Xia H; Sun F; Xiong A; Luo J; Zhang L; Yu H; Liu M; Liu H; Wang H; Zhang H; Chen C; Wu C; Duan L; Zhu Y; Zhang P; Jiang G
BMC Med; 2022 Dec; 20(1):493. PubMed ID: 36581917
[TBL] [Abstract][Full Text] [Related]
13. Development of postoperative bronchopleural fistula after neoadjuvant immunochemotherapy in non-small cell lung cancer: case reports and review of the literature.
Zhao R; Guan X; Zhang P; Liu Y; Xu Y; Sun C; Qiu S; Zhu W; Yang Z; Wang X
J Cancer Res Clin Oncol; 2024 Apr; 150(4):175. PubMed ID: 38573518
[TBL] [Abstract][Full Text] [Related]
14. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with
Chemotherapy in Resectable Non-small Cell Lung Cancer].
Zhou S; Hao X; Yu D; Liu S; Cao X; Su C; Song X; Xiao N; Li Y; Yang W; Zhao D; Wang J; Liu Z; Xu S
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):420-425. PubMed ID: 34024062
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis.
Yu Z; Xu F; Zou J
Eur J Clin Pharmacol; 2024 Apr; 80(4):505-517. PubMed ID: 38300281
[TBL] [Abstract][Full Text] [Related]
16. Organ preservation strategies after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a multicenter retrospective cohort study.
Hui B; Wang X; Wang X; Qiao B; Duan J; Shang R; Yang W; Wang J; Chen K; Yang F; Jiang T; Lei J
Int J Surg; 2023 Aug; 109(8):2286-2292. PubMed ID: 37161431
[TBL] [Abstract][Full Text] [Related]
17. Multi-organs perioperative immune-related adverse events and postoperative bronchial anastomotic fistula in a patient receiving neoadjuvant immunotherapy with NSCLC.
Xu Y; Lyu X; Qin Y; Ma D; Wang M; Shi J; Long Y; Tang B; Liu H
Thorac Cancer; 2022 Aug; 13(16):2340-2345. PubMed ID: 35815431
[TBL] [Abstract][Full Text] [Related]
18. Robotic-assisted thoracic surgery following neoadjuvant chemoimmunotherapy in patients with stage III non-small cell lung cancer: A real-world prospective cohort study.
Gao Y; Jiang J; Xiao D; Zhou Y; Chen Y; Yang H; Wang L; Zeng J; He B; He R; Li M; Liu Z
Front Oncol; 2022; 12():969545. PubMed ID: 35992784
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: case series and literature review.
Yin C; Hu B; Yang X; Kou L; Tian B; Wang C; Li S; Liu B; Ge J
World J Surg Oncol; 2023 Sep; 21(1):304. PubMed ID: 37749594
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.
Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S
JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]